Pantarhei Bioscience B.V.
http://www.pantarheibio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pantarhei Bioscience B.V.
Palatin ploughs barren female sexual dysfunction field
New Jersey's Palatin Technologies has initiated a pivotal Phase III trial for its female sexual dysfunction (FSD) drug bremelanotide, ploughing ahead in what appears to be a difficult area. Companies which have attempted to till this field have typically found their crops lacking, and Palatin itself is no stranger to the FSD drought.
Roche in $1.7bn deal for breast cancer innovator Seragon
Roche's Genentech business has agreed to pay $725m up front and up to $1bn in milestone-related payments to acquire Seragon Pharmaceuticals of San Diego, California. Seragon's most advanced product is in Phase I trials, but Roche believes its technology could herald a breakthrough in cancer treatment.
Emerging Players In Contraceptives Could Reshape A Mature Market
The highly competitive, extensively generic contraceptive market has long been characterized by incremental changes in hormone dose, delivery and regimen. But Actavis’ emergence over the past year as a new powerhouse in women’s health is setting the stage for the first new estrogen component in years.
BioSante's triple OC promising
A triple-hormone oral contraceptive, "Pill-Plus", that contains an androgen as well as an oestrogen and a progestogen, could be of use in women with reduced sexual function, according to the US firm BioSante Pharmaceuticals.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice